TIDMAKR
Akers Biosciences, Inc.
12 May 2015
For immediate release: 12 May 2015
Akers Biosciences Introduces New Rapid Breath Ketone and
Oxidative Stress Tests to the Health and Wellness Industry
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a medical device company focused on
reducing the cost of healthcare through faster, easier diagnostics,
introduced two new breath tests to the U.S. market from the
Company's Akers Wellness division at the World Congress on
Anti-Aging Medicine in Hollywood, Florida, USA last week.
BreathScan(R) OxiChek(TM) ("OxiChek(TM)") and BreathScan(R)
KetoChek(TM) ("KetoChek(TM)"), together with the
Bluetooth(R)-enabled reading device, BreathScan Lync(TM) - which
synchs via an app on any mobile device - will enable users to
monitor trends in critical metabolic processes. The products will
provide healthcare professionals, suppliers of nutritional
supplements and weight loss plans, as well as health coaches, the
ability to more effectively demonstrate, monitor and adjust the
efficacy of their products and the progress of their clients. These
products may also provide such customers with an opportunity for
significant revenue enhancement through distribution for in-office
and at-home use of the devices.
OxiChek(TM) is the first disposable breath test to rapidly
determine levels of oxidative stress (free radicals) in the body.
OxiChek(TM) measures the most abundant free radicals, including
superoxides, hydrogen peroxide and aldehydes - unlike some
pre-existing devices which measure only one. Frequent use of
OxiChek(TM) may help users comply with and adhere to their regimen
of nutritional supplementation for management of oxidative stress,
which is implicated in many diseases including cardiac, cancer and
arthritic diseases.
KetoChek(TM) is a second generation enhancement of the Company's
METRON(R) breath ketone test. KetoChek(TM), to our knowledge, is
the only disposable breath-based diagnostic device that provides
rapid, quantitative assessment of the presence of ketones, to
determine if the subject is in the optimal fat-burning state for
weight loss, known as ketosis. Achieving a state of ketosis is a
goal of many individuals following low carbohydrate, ketogenic
diets. KetoChek(TM) is a simple, non-invasive test to track and
monitor for ketosis in individuals interested in maximizing weight
loss, as well as endurance athletes wanting to activate fat-burning
metabolism.
The innovative BreathScan Lync(TM) device works with both
OxiChek(TM) and KetoChek(TM), to display and track results over
time via Bluetooth(R), to any iOS (Apple) or Android mobile
device.
"We believe that personalized health information is the wave of
the future and that this suite of BreathScan products, including
OxiChek(TM), KetoChek(TM) and the BreathScan Lync(TM), will provide
tremendous value to healthcare professionals, consumers, and diet
and supplement manufacturers within the health and wellness
industry," said Raymond F. Akers, Jr. PhD, Co-founder and Executive
Chairman.
"Our KetoChek(TM) test can help individuals achieve ketosis,
which is a state of optimal fat burning, while OxiChek(TM) can help
them better optimize lifestyle and supplement utilization to
control free radical levels. Since higher free radical levels have
been shown to correlate with age, OxiChek(TM) is providing
important information that can greatly enhance an individual's
ability to take control of their aging process," continued Dr.
Akers.
"Health and wellness is a trillion dollar business globally and
our proprietary technology for testing breath condensate is a
highly effective diagnostic tool for professionals and consumers in
this industry. Whether in health and wellness or medical
diagnostics, our faster, easier diagnostic tests provide
information that make lives better," added Dr. Akers.
The Company is in discussions with a number of strategic
partners specializing in the health and wellness industry with
regards to the commercialization of OxiChek(TM), KetoChek(TM), and
BreathScan Lync(TM).
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbiosciences.com. Follow us on Twitter
@AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Taglich Brothers, Inc. (US Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Vigo Communications (UK Investor Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGLGDUCBBBGUD
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From May 2024 to Jun 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Jun 2023 to Jun 2024